Combination of a long-acting amylin analog (cagrilintide) and a GLP-1 agonist (semaglutide). Synergistically slows gastric emptying, suppresses glucagon, increases insulin secretion and satiety. Clinical trials showed ~20% weight reduction.
Appetite Regulation
Peptides mimic satiety hormones, reducing hunger signals from the brain.
Quickstart Highlights
- Dosage: Per plan
- Frequency: Weekly
- Administration: Subcutaneous
- Cycle length: Chronic
How This Works
Cagrilintide
2.5-5mg per doseLong-acting amylin analog for satiety
Semaglutide
2.5-5mg per doseGLP-1 receptor agonist for appetite and glycemic control
Mechanism of Action
How CagriSema Works in Your Body
Peptide Administered
Enters bloodstream and travels to target receptors
Brain Signaling
Binds to GLP-1 receptors in the hypothalamus
Appetite Reduced
Signals satiety — you feel full sooner
Fat Metabolism
Body shifts to burning stored fat for energy
Benefits & Side Effects
Potential Benefits
- Enhanced weight loss
- Appetite suppression
- Glycemic control
- Synergistic effects
Quick notes
More effective than monotherapy. Investigational. Nausea risk during titration.
References
Community Insights
Summarised from 1 sourceCombination of a long-acting amylin analog (cagrilintide) and a GLP-1 agonist (semaglutide). Synergistically slows gastric emptying, suppresses glucagon, increases insulin secretion and satiety. Clinical trials showed ~20% weight reduction. More effective than monotherapy. Investigational. Nausea ri
Common Dosages Reported
- Per plan Weekly
- Standard protocol dosing
Side Effects Mentioned
- Generally mild, individual variation expected
- See full guide for detailed safety info
Stacking Suggestions
- Consult research and healthcare provider before stacking
What people are saying
Results vary based on individual response
Consistent dosing and timing important
Reviews & Discussion
Real experiences shared by the community — not medical advice.
Comparison of CagriSema Efficacy and Side Effects
A user discussed CagriSema in the context of clinical trial data, noting its high efficacy with an average weight loss of 22.7%. However, they highlighted that the Cagrilintide component is non-selective and can cause increased nausea and 'conditioned taste avoidance' compared to newer selective amylin agonists.
Switching from Semaglutide to CagriSema for weight loss stalls
A user reported switching to a CagriSema blend after two months on micro-doses of semaglutide. While they felt physically well on the original regimen, weight loss had been very slow, prompting the transition to the combination therapy.
No discussion yet — be the first.
No notes yet — be the first.